Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. (Q40449697)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17508219%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

title

Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17508219%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

0 references

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17508219%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Timothy Synold

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17508219%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Don J. Diamond

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17508219%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

5

Simon F Lacey

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17508219%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

8

Janice P Dutcher

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17508219%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

author name string

Kim Margolin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17508219%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Primo Lara

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17508219%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Paul Frankel

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17508219%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Tracey Baratta

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17508219%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Bixin Xi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17508219%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

David R Gandara

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17508219%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

publication date

17 May 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17508219%20AND%20SRC:MED&resulttype=core&format=json

Journal of Cancer Research and Clinical Oncology

30 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17508219%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

volume

133

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17508219%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17508219%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

page(s)

705-711

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17508219%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00432-007-0200-6

30 December 2019

exact match

0 references

cites work

bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00432-007-0200-6

Immunomodulating therapy with rIL-2 and interferon alpha-induces in vivo expression of Bcl-2, Fas (APO-1/CD95), and Fas ligand on peripheral lymphocytes (a pilot study)

21 January 2018

1 reference

12 December 2020

The von Hippel-Lindau gene product inhibits renal cell apoptosis via Bcl-2-dependent pathways

1 reference

12 December 2020

Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers.

1 reference

12 December 2020

Interferon in metastatic renal cell carcinoma.

1 reference

12 December 2020

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

Bcl-2 proto-oncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma

1 reference

12 December 2020

Renal lesions in von Hippel-Lindau disease: immunohistochemical expression of nephron differentiation molecules, adhesion molecules and apoptosis proteins

1 reference

12 December 2020

Expression of bcl-2 in small cell lung carcinoma cells.

1 reference

12 December 2020

Expression of the bcl-2 gene product in follicular lymphoma

1 reference

12 December 2020

Apoptosis and expression of the bcl-2 proto-oncogene in the fetal and adult human kidney: evidence for the contribution of bcl-2 expression to renal carcinogenesis

1 reference

12 December 2020

Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18)

1 reference

12 December 2020

Characterization and quantification of Bcl-2 antisense G3139 and metabolites in plasma and urine by ion-pair reversed phase HPLC coupled with electrospray ion-trap mass spectrometry

1 reference

12 December 2020

Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides

1 reference

12 December 2020

Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.

1 reference

12 December 2020

Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas

1 reference

12 December 2020

Bcl-2 modulates Fas-mediated apoptosis in human renal cell carcinoma cell lines

1 reference

12 December 2020

bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis

1 reference

12 December 2020

Interleukin-2 in the treatment of renal cancer

1 reference

12 December 2020

Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells

1 reference

12 December 2020

Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia.

1 reference

12 December 2020

A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer

1 reference

12 December 2020

Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity.

1 reference

12 December 2020

The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients.

1 reference

12 December 2020

Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer

1 reference

12 December 2020

Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase.

1 reference

12 December 2020

Antisense strategies for oncogene inactivation

1 reference

12 December 2020

A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma

1 reference

12 December 2020

A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer

1 reference

12 December 2020

Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer

1 reference

12 December 2020

The Bcl-2 protein family: arbiters of cell survival

1 reference

12 December 2020

10.1007/S00432-007-0200-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17508219%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference